Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 3370
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT00059748 Studies of the Natural History, Pathogenesis, and Outcome of Autoinflam… |
Studies of the Natural History, P… | Myopathies | À vérifier | COMPLETED | En attente / non publié | National Institute of Arthritis a… | United States · National Institutes of Health Clinica… | 2003-05-09 | Ouvrir |
| NCT05650567 Study of M5049 in DM and PM Participants (NEPTUNIA) |
M5049 dose | Myopathies | Phase 2 | TERMINATED | En attente / non publié | EMD Serono Research & Development… | United States, Czechia, Greece, Italy, Poland, Spain,… | 2023-01-19 → 2025-06-25 | Ouvrir |
| NCT05637112 ASTER — A Treatment Effectiveness Study Among SLE Patients Receiving An… |
ASTER — A Treatment Effectiveness… | Lupus | À vérifier | ACTIVE_NOT_RECRUITING | En attente / non publié | AstraZeneca | Austria, Belgium, Canada, France, Germany, Israel, It… | 2023-02-27 → 2030-12-30 | Ouvrir |
| NCT07800871 FT839 in Autoimmune Diseases |
FT839 | Lupus | Phase 1/2 | RECRUITING | En attente / non publié | Fate Therapeutics | United States · Providence Medical Foundation, Fuller… | 2026-10 → 2040-10 | Ouvrir |
| NCT07544225 CELL-ATTACK 1 — Study Investigating the Safety of Anti-CD19 CAR-T Cells… |
anti-CD19 CAR-T cells | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Gustave Roussy, Cancer Campus, Gr… | France · Gustave Roussy, Villejuif, France | 2026-12-01 → 2043-02-01 | Ouvrir |
| NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3… |
Sonrotoclax | Cancer | Phase 3 | RECRUITING | En attente / non publié | BeOne Medicines | United States, Australia, Brazil, Canada, China, Czec… | 2026-01-22 → 2031-11 | Ouvrir |
| NCT07815665 HARMONi-GU1 — A Study of Ivonescimab in Combination With Enfortumab Ved… |
Ivonescimab Dose 1 | Cancer | Phase 2/3 | RECRUITING | En attente / non publié | Summit Therapeutics | United States · Research Site, Jacksonville, United S… | 2026-09-10 → 2030-12-31 | Ouvrir |
| NCT07729384 Strengthening Teen Brain Resilience Using Music Intervention to Improve… |
Music Therapy | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Mayo Clinic | United States · Mayo Clinic in Arizona, Scottsdale, U… | 2026-10-01 → 2028-11-01 | Ouvrir |
| NCT07365241 A Study to Evaluate Adverse Events and Change in Disease Activity of In… |
ABBV-706 | Cancer | Phase 3 | RECRUITING | En attente / non publié | AbbVie | United States, Austria, Belgium, France, Germany, Gre… | 2026-07-02 → 2030-09 | Ouvrir |
| NCT07799740 LIRA — Examination of Rectal Blood Supply During Rectal Cancer Surgery … |
Laser speckle contrast imaging | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | University of Aarhus | Denmark · Regional Hospital Gødstrup, Herning, Denmar… | 2026-09-01 → 2029-06-01 | Ouvrir |
| NCT05099003 A Study of the Drug Selinexor With Radiation Therapy in Patients With N… |
Biopsy Procedure | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States, Australia, Canada, New Zealand · Alban… | 2022-05-31 → 2027-06-30 | Ouvrir |
| NCT07815262 ArtRehab — Study on the Efficacy and Safety of "Body-Tuning, Voice-Tuni… |
ArtRehab — Study on the Efficacy … | Cancer | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | Keda Yu | China · Shanghai Cancer Hospital, Fudan University, S… | 2026-04-01 → 2027-03-01 | Ouvrir |
| NCT04665765 Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide … |
carboplatin | Cancer | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · City of Hope Medical Center, Duarte, … | 2021-01-18 → 2027-06-28 | Ouvrir |
| NCT07401381 SIE-1 — A Study to Compare the Steady-State Bioavailability of Injectab… |
US-sourced oral Femara® + Letrozo… | Cancer | Phase 1 | RECRUITING | En attente / non publié | Rovi Pharmaceuticals Laboratories | United States, Serbia, Spain · Althaia Xarxa Assisten… | 2026-06-08 → 2028-10 | Ouvrir |
| NCT06303505 NAPISTAR1-01 — FiH Study to Investigate Safety, PK and Efficacy of the … |
TUB-040 | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | Tubulis GmbH | United States, Belgium, Germany, Puerto Rico, Romania… | 2024-06-12 → 2027-12 | Ouvrir |
| NCT04381130 A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer |
EF-009 | Cancer | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | Everfront Biotech Co., Ltd. | Non communiqué | 2027-04-01 → 2030-06-30 | Ouvrir |
| NCT07593079 Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Resi… |
Bicalutamide | Cancer | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Washington University School of M… | United States · Washington University School of Medic… | 2026-10-31 → 2028-01-31 | Ouvrir |
| NCT07278739 Testing an Educational Program to Improve Goals of Care Conversations B… |
Testing an Educational Program to… | Cancer | Non applicable | RECRUITING | En attente / non publié | SWOG Cancer Research Network | United States · CARTI Cancer Center, Little Rock, Uni… | 2026-08-07 → 2032-07-21 | Ouvrir |
| NCT07815704 Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Ef… |
Targeting Immune Modulation in Hi… | Cancer | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | University of Colorado, Denver | United States · University of Colorado Anschutz, Auro… | 2026-09 → 2031-08 | Ouvrir |
| NCT07729241 COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival |
COVICI-SURV: COVID-19 Vaccination… | Cancer | À vérifier | COMPLETED | En attente / non publié | Groupe Hospitalier Pitie-Salpetri… | France · Hôpital Pitié Salpêtrière / CIC-2503, Paris,… | 2020-12-28 → 2026-09-10 | Ouvrir |
| NCT05985954 Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib i… |
Cetuximab | Cancer | Phase 1 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · M D Anderson Cancer Center, Houston, … | 2024-01-18 → 2028-03-28 | Ouvrir |
| NCT07104253 Establishing Feasibility of Transbronchial Cryoablation With an In-Deve… |
Ex vivo cryo-ablation | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Endocision Technologies Inc. | Non communiqué | 2026-12 → 2028-12 | Ouvrir |
| NCT07814365 PBI for Low-risk Breast Cancer |
3-week PBI | Cancer | Non applicable | RECRUITING | En attente / non publié | Fudan University | China · Fudan University Shanghai Cancer Center, Shan… | 2021-09-16 → 2031-09-16 | Ouvrir |
| NCT07810439 PROTECT-Africa: Biomarker Validation for Preeclampsia Triage |
PROTECT-Africa: Biomarker Validat… | Hypertension | À vérifier | RECRUITING | En attente / non publié | Africa Clinical Research Network … | Zimbabwe · Mutala Trust, Harare, Zimbabwe | 2026-02-05 → 2027-02-28 | Ouvrir |
| NCT03549754 iCaReMe Global Registry: Multinational Real-world Evidence in Cardioren… |
iCaReMe Global Registry: Multinat… | Hypertension | À vérifier | RECRUITING | En attente / non publié | AstraZeneca | Brazil, Chile, Costa Rica, Côte d’Ivoire, Egypt, Geor… | 2018-02-17 → 2030-12-31 | Ouvrir |